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LRosuvastatin attenuates bioprosthetic heart
valve calcificationSak Lee, MD, PhD, Dae-Hyun Kim, DVM, PhD, Young-Nam Youn, MD, PhD, Hyun Chel Joo, MD,
Kyung-Jong Yoo, MD, PhD, and Seung Hyun Lee, MD, PhDABSTRACT
Objective: There are pathophysiologic similarities between calcification and
atherosclerosis because both are the product of an active inflammatory process.
The aim of the study was to examine the effects of statin treatment on calcification
in commercially available bioprosthetic heart valves.
Methods: Twenty Sprague–Dawley rats were fed a high-fat diet to induce hyper-
cholesterolemia during 4 weeks. They were randomly divided into 2 groups ac-
cording to statin intake (control, n ¼ 10: high-fat diet/statin; n ¼ 10: high-fat
diet with statin). Four commercially available tissue valve (Magna Perimount,
Carpentier-Edwards, Irvine, Calif; Hancock, Medtronic, Minneapolis, Minn; Mi-
troflow, LivaNova, London, England; and Trifecta, St Jude Medical, St Paul,
Minn) cusp samples (total 320) were implanted in rat dorsal subcutis at 4 weeks.
After implantation, rosuvastatin was administered daily to the statin group. The
cusps were explanted at 12 weeks, and calcium levels were determined by atomic
absorption spectroscopy. Western blotting, histologic, and immunohistochemical
analyses were conducted to identify the anticalcification mechanism of the statin.
Results: The mean calcium level in the control group was significantly higher
than in the statin group (P < .01) for all tissue valves (Magna Perimount:
2.67  0.26 mg/g vs 1.31  0.40 mg/g; Hancock: 2.70  0.57 mg/g vs
1.53  0.34 mg/g; Mitroflow: 2.39  0.71 mg/g vs 1.26  0.38 mg/g; Trifecta:
2.54  0.42 mg/g vs 1.63  0.72 mg/g). Inflammatory cell infiltration and
interleukin-6 and bone morphogenetic protein 2 expressions were significantly
reduced in the statin group.
Conclusions: Statin treatment significantly attenuated bioprosthetic heart valve
calcification associated with decreasing the levels of interleukin-6 and bone
morphogenetic protein 2. Thus, statin treatment might be helpful for the longevity
of bioprosthetic heart valves. (J Thorac Cardiovasc Surg 2019;158:731-41)From the Division of Cardiovascular Surgery, Department of Thoracic and Cardiovas-
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Statin attenuated bioprosthetic valve calcification.cCentral Message
Statin attenuated the calcification of BHV in a
rat model and should be considered for
reducing BHV calcification possibly induced
from inflammation.Perspective
BHVs have the propensity to undergo structural
degeneration, limiting their durability and often
necessitating reoperation. Statin treatment
significantly attenuated BHV calcification,
which seems to be associated with decreasing
the expression levels of IL-6 and BMP-2.See Commentaries on pages 742 and
744.Since the first implants of heterologous bioprosthetic heart
valve (BHVs) in the 1960s, various improvements to tissue
valve design and manufacturing have been made. BHVshave central flow and a high freedom from thrombus forma-
tion and usually do not require anticoagulation treatment.
However, BHVs have the propensity to undergo structural
degeneration, limiting their durability and often necessi-
tating reoperation.1,2 A study of the causes of valve
failures requiring reoperation reported that sterile
degeneration or primary tissue failure accounted for 74%
of BHV.3 The degeneration of BHV is believed to depend
on the mechanical properties of the valve and onthis QR code will
to the article title
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VIDEO 1. I’m Dr Seung Hyun Lee from Yonsei University (Seoul, Ko-
rea). Since the first implants of heterologous BHVs in the 1960s, various
improvements to tissue valve design and manufacturing have been made.
BHVs have central flow and a high freedom from thrombus formation
and usually do not require anticoagulation treatment. However, BHVs
have the propensity to undergo structural degeneration, limiting their dura-
bility and often necessitating reoperation. The degeneration of BHV is
believed to depend on the mechanical properties of the valve and on immu-
nologic and calcification processes. Similarities between the mechanisms
and the risk factors for atherosclerosis, native valve calcification, and post-
operative BHV degeneration recently have been proposed. A few studies
have shown that statin treatment can reduce calcific degeneration of native
aortic valves. Some studies have revealed a potential relationship between
statin treatment and the durability of BHV, with statins appearing to slow
the progression of BHV. In our previous pilot study, we evaluated, in a
rat subdermal implantation model, the effects of a specific statin therapy,
rosuvastatin (Crestor, HMG-CoA reductase inhibitor, rosuvastatin calcium,
AstraZeneca Pharmaceuticals LP), on postimplantation tissue changes of
bovine aortic valve bioprosthesis, and the statin significantly attenuated
the calcification of the bioprosthesis in a rat subdermal implantation model.
Serially, the aim of the present study was to evaluate the effects of statin
therapy on postimplantation tissue changes in various commercially
available BHVs. This presentation is about full process of my experiment.
Video available at: https://www.jtcvs.org/article/S0022-5223(18)33481-0/
fulltext.
Abbreviations and Acronyms
BHV ¼ bioprosthetic heart valve
BMP-2 ¼ bone morphogenetic protein 2
IL ¼ interleukin
LDL ¼ low-density lipoprotein
LLT ¼ lipid-lowering therapy
Tchol ¼ total cholesterol
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Timmunologic and calcification processes.4 Similarities be-
tween the mechanisms and the risk factors for atheroscle-
rosis, native valve calcification, and postoperative BHV
degeneration have been proposed recently.3,5 In addition,
chronic inflammatory change in the leaflet, including
infiltration of macrophages and T lymphocytes and
lipoprotein deposition in the areas of calcification, has
prompted researchers to investigate whether a medical
intervention can be applied to slow the progression of
valvular failure. This concept has introduced a new
perspective on the prevention and treatment of BHV
failure. A few studies have shown that statin treatment can
reduce calcific degeneration of native aortic valves.5-7
Some studies have also revealed a potential relationship
between statin treatment and the durability of BHV, with
statins appearing to slow the progression of BHV.8,9 In our
previous study, we evaluated, in a rat subdermal
implantation model, the effects of a specific statin therapy,
rosuvastatin (Crestor, HMG-CoA reductase inhibitor, rosu-
vastatin calcium, AstraZeneca Pharmaceuticals LP, Gai-
thersburg, Md), on postimplantation tissue changes in a
commonly used bovine aortic valve bioprosthesis.10 Our re-
sults suggested that the statin could significantly attenuate
the calcification of the bioprosthesis in a rat subdermal im-
plantation model and might thereby prolong the durability
of the bioprosthesis. However, only 1 type of bioprosthetic
valve (a Carpentier-Edwards Perimount aortic valve, Irvine,
Calif) was used in our previous experiment, so we did not
obtain information about a range of commonly used tissue
valves. Therefore, the aim of the present study was to eval-
uate the effects of statin therapy on postimplantation tissue
changes in various commercially available BHVs (Video 1).
MATERIALS AND METHODS
Animals, Diets, and Experimental Design
This animal study was approved by the Institutional Animal Care and
Use Committee of Yonsei University Health System (2014-0365). Twenty
healthy 2-month-old Sprague-Dawley rats weighing 390.34 12.28 gwere
used in the present study. The animals were acclimatized to a breeding
room for 1 week. All 20 rats were fed a high-fat diet containing 1.25%
cholesterol and 0.5% cholic acid (TD.02028, Harlan Korea Laboratories
Co, Ltd, Seoul, Korea) for 12 weeks to induce hypercholesterolemia.
Serum lipid levels were measured just before the high-fat diet was intro-
duced and at 4 and 12 weeks. Samples of 4 different bioprosthetic valve
cusps were surgically implanted in the dorsal subcutis at 4 weeks. The
rats were then randomly allocated to the control group (n ¼ 10, high-fat732 The Journal of Thoracic and Cardiovascular Surgdiet only) or the statin group (n ¼ 10, high-fat diet with statin treatment).
After implantation of the valve cusps, rosuvastatin was administered daily
to the statin group. The cusps were explanted at 12weeks, and their calcium
levels were determined by atomic absorption spectroscopy. Western blot-
ting, histologic, and immunohistochemical analyses were conducted to
determine the anticalcification mechanism of the statin.
Measurement of the Blood Lipid Profile and
Interleukin-6 Level/Immunohistochemistry
Nonfasting blood lipid profiles for total cholesterol (Tchol) and low-
density lipoprotein (LDL) cholesterol were measured just before the
high-fat diet was introduced and at 4 and 12 weeks for validation of hyper-
cholesterolemia. To collect the blood, the animals were anesthetized with
10 mg/kg of xylazine and 30 mg/kg of Zoletil (Virbac, Carros, France).
Then, 1.3 mL of blood was aseptically obtained from the subclavian vein
and 0.5 mL of the blood sample was placed into a heparin tube, and the re-
maining 0.8 mL was placed into a serum-separating tube. Plasma samples
were obtained by centrifugation at 6000 rpm for 5 minutes at room temper-
ature. LDL cholesterol and Tchol were measured by enzymatic colori-
metric assay (Modular Analytics, Roche, Germany). Serum samples
were obtained by centrifugation at 14,000 rpm for 10 minutes at 4C andery c September 2019
Edwards
Hancock
Mitroflow
Trifecta
BA
1
3
2
4
1
2
3
4
2 3
4 1
3 4
1 2
4 1
2 3
FIGURE 1. Basic schematics of the rat experimental model. A, Four different commercial BHVs were used. Three were bovine pericardial valves
(Carpentier-Edwards Perimount aortic valve, Irvine, Calif; St Jude Trifecta, St Paul, Minn; and LivaNovaMitroflow, London, England), and 1 was a porcine
pericardial valve (Medtronic Hancock II, Minneapolis, Minn). Each leaflet was then incised along the frame of the BHVs using a number 11 surgical blade.
Then, round patches were gained using a 4-mm skin biopsy punch for implantation of rat dorsal subcutis. B, Four round patches per each commercial BHV
(total 16 patches per a rat in 4 companies, each group 160 pieces, total 320 pieces) were surgically implanted into the dorsal subcutis of each rat. To avoid
position effects, each BHV patch group (4 same company patches) was rotated serially in each quadrant site.
TABLE 1. Intergroup comparison of the lipid profile results
Statin group Control group P valve
Tchol (pre-) (mg/dL) 70.80  7.50 72.40  11.04 NS
LDL (pre-) (mg/dL) 14.70  3.47 15.10  3.96 NS
Tchol (4 wk) (mg/dL) 280.10  97.17 267.80  61.15 NS
LDL (4 wk) (mg/dL) 201.50  80.86 190.40  57.41 NS
Tchol (12 wk) (mg/dL) 181.50  57.12 257.30  30.10 <.01
LDL (12 wk) (mg/dL) 130.10  49.35 227.50  57.00 <.01
Tchol, Total cholesterol; NS, not significant; LDL, low-density lipoprotein.
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Tstored at70C until further analysis. Serum interleukin (IL)-6 levels were
measured at 12 weeks using enzyme-linked immunosorbent assay kits
(Quantikine, Rat IL-6 Immunoassay kit, R&D Systems, Minneapolis,
Minn). Macrophages were identified by staining tissue sections with
commercially available antibodies to macrophage marker MAC387 (con-
centration 1:100).
Animal Experiment
Four different commercial BHVs were used in this study. Three were
bovine pericardial valves (Perimount, Carpentier-Edwards; Trifecta, St
Jude Medical, St Paul, Minn; and Mitroflow, LivaNova, London, England),
and 1 was a porcine pericardial valve (Hancock II, Medtronic Inc, Minne-
apolis, Minn). Each BHVwas rinsed for at least 15 minutes with 500 mL of
sterile physiologic saline solution and then transferred to another rinse ba-
sin containing sterile saline. Each leaflet was then incised along the frame
of the BHV using a number 11 surgical blade. Then, round patches were
gained using a 4-mm skin biopsy punch (Figure 1, A).
Four weeks after hypercholesterolemia induction, 4 round patches per
BHV (total 16 patches per a rat) were surgically implanted into the dorsal
subcutis of each rat. To avoid position effects, each BHV patch group
(4 same company patches) was rotated serially in each quadrant site
(Figure 1, B). Each animal was intraperitoneally injected with 10 mg/kg
of xylazine and 30 mg/kg of Zoletil. After placing the animal in ventral re-
cumbency, a dorsal midline skin incision was made. Then, 4 trimmed peri-
cardial patches were implanted subcutaneously in each quadrant and fixed
with a 6-0 polypropylene suture. The subcutaneous layer was sutured with
a simple continuous pattern using 5-0 polyglyconate, and the skin was
closed with a simple interrupted pattern using 4-0 nylon. For 3 days after
surgery, 20 mg/kg of gentamicin and 1 mg/kg of meloxicam were injected
subcutaneously for infection prophylaxis and analgesia, respectively.
For 8 weeks from the day after surgery, 20 mg/kg/d of rosuvastatin in
2 mL of normal saline was given to the statin group by oral gavage using
an 18-gauge feeding tube with adequate restraint.11 The rats’ body weights
were measured every week to calculate the drug dosage. The control group
was given 2 mL of normal saline only.The Journal of Thoracic and CaQuantitative Calcium Determination
At 8weeks after surgery, the animals were euthanized by CO2 inhalation
and the implanted valve samples were collected. After cleanly removing
the surrounding connective tissue from the implants, they were frozen
for 24 hours at 80C. Moisture was removed from the samples by using
a freeze-dryer for 24 hours, and then the samples were weighed and then
placed in 5 mL of aqua regia in a 100-mL beaker. The beaker was slowly
heated on a hot plate for 6 hours at 70C to 80C to avoid tissue disruption
from rapid thawing and rewarming, followed by 5 hours at 140C to 150C;
5 mL of H2O2 was then added. The calcium content of the samples was
analyzed using a Perkin Elmer Optima 8300 ICP-OES spectrometer
(Norwalk, Conn).
Histopathologic and Immunohistochemical
Evaluation
Extracted BHV tissue samples were fixed in 10% neutralized buffered
formalin (BBC Biochemical, Mount Vernon, Wash) and processed using
standard methods and embedded in paraffin. Sections 4-mm thick were
stained with hematoxylin (Sigma-Aldrich, St Louis, Mo) and eosin (BBC
Biochemical). For immunohistochemistry, the sections were deparaffinized
using standard protocols, and antigen retrieval was performed withrdiovascular Surgery c Volume 158, Number 3 733
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FIGURE 2. Lipid profile difference between groups and change through experiment. All 20 rats were fed a high-fat diet for 12 weeks to induce hypercho-
lesterolemia. Serum lipid levels were measured just before the high-fat diet was introduced and at 4 and 12 weeks. Samples of 4 different bioprosthetic valve
cusps were surgically implanted in the dorsal subcutis at 4 weeks. For checking adequate hyperlipidemia in all rats, serum lipid levels (ex), Tchol level, and
LDLwere checked at 4 weeks. After implantation, the statin group was given 20mg/kg/d rosuvastatin in 2 mL of normal saline: control group (n¼ 10, high-
fat diet only) or statin group (n ¼ 10, high-fat diet with statin treatment). Statin group showed a significantly low lipid profile after 12 weeks. A, Preim-
plantation Tchol level was similar in groups (control, n ¼ 10 vs statin, n ¼ 10). Preimplantation Tchol level between statin and control groups:
70.80 7.50 versus 72.40 11.04 (control box: 65.25-78, median: 70.5, 5996/statin box: 66.5-72.75, median: 71, 5988). B, Preimplantation LDL level
was similar in groups (control, n ¼ 10 vs statin, n ¼ 10). Preimplantation LDL level between statin and control groups: 14.70  3.47 versus 15.10  3.96
(control box: 12.5-15.75, median: 14, 1123/statin box: 12.25-16, median: 14.5, 1021). C, Both groups showed appropriate hyperlipidemia status (con-
trol, n ¼ 10 vs statin, n ¼ 10). Postimplantation (4 weeks) Tchol level (just before initiation of statin treatment) between statin and control groups:
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TTris-EDTA (pH 9.0) buffer. Then, sections were incubated for 10 minutes
in 3% hydrogen peroxide (Duksan Hydrogen Peroxide 3059, Kyungkido,
Korea) to inactivate endogenous peroxidase and blocked by incubating for
1 hour in 5% bovine serum albumin. Subsequently, the sections were
labeled with the following primary mouse monoclonal antibodies (Abcam,
Cambridge, United Kingdom: anti–IL-6) (ab6672), antimacrophage
(MAC387, ab22506), and anti-bone morphogenetic protein 2 (BMP-2)
(ab6285). The antibody-labeled sections were then incubated with Dako
EnVisionþ System-HRP-labeled polymer antimouse kit solution
(Dako4001, Dako, Glostrup, Denmark). DAP (K-3468, Dako) staining
was performed for 3 minutes at room temperature for tissue visualization.
Sections were then counterstained with hematoxylin.
Eight pictures of each sample were obtained at3400 magnification and
used for cell counts. Counts of infiltrated cells or immunostaining positive
cells within the implants were performed blindly by an objective
pathologist.
Western Blot Analysis
To investigate the expression of IL-6 and BMP-2, samples were stored at
70C. Protein was extracted with 500 mL of PRO-PREP protein extrac-
tion solution (Intron Biotechnology, Kyungki-Do, Korea), followed by tis-
sue homogenization using sharp scissors. After 30 minutes on ice, the
samples were centrifuged at 14,000 rpm for 10 minutes at 4C. The super-
natant containing the protein lysates was then collected.
The protein content was quantified using a protein-assay kit (Bio-Rad,
Hercules, Calif). For immunoblotting, 50 mg of total protein extract was
mixed with Laemmli sample buffer and transferred to a Mini Protean
TGX precast gradient gel (Bio-Rad) with DOKDO-MARK (Intron
Biotechnology) as the standard prestained protein marker. Gel electropho-
resis was performed with a Mini Protean system (Bio-Rad) applying 100 V
for 130 minutes. After electrophoresis, proteins were blotted to a methanol
preactivated polyvinylidene difluoride membrane applying 230 mAh for
90 minutes using a Mini Trans-Blot Cell (Bio-Rad). The blotted mem-
branes were then blocked and incubated with anti–BMP-2 antibody
(ab6285, 1:1000 dilution, Abcam) and anti–IL-6 antibody (ab6672,
1:1000 dilution, Abcam) in PBS-T with 5% skimmed milk. Anti–b-actin
antibody was used as a loading control (ADI-905-733, 1:2000 dilution,
Enzo Life Sciences, New York, NY). After incubation with the primary an-
tibodies, the membranes were washed with PBS-T buffer 3 times and then
incubated with secondary goat anti-mouse immunoglobulin-G horseradish
peroxidase (ab6789, 1:2000 dilution, Abcam) for the anti–BMP-2 antibody
and anti-Il6 antibody and goat anti-rabbit immunoglobulin-G horseradish
peroxidase (ADI-SAB-300-J, 1:2000 dilution, Enzo Life Sciences) for
the anti–b-actin antibody. Proteins were detected using an enhanced chem-
iluminescence detection reagent for immunoblot analysis (Daeill Lab Ser-
vice, Seoul, Korea). Subsequently, quantitative analysis was performed
with the pixel density analysis method using Image J software (National In-
stitutes of Health, Bethesda, Md). Relative density was defined as (specific
band density/b-actin band density) 3 100.
Statistical Analysis
All data were expressed as mean  standard deviation. Statistical ana-
lyses were performed using GraphPad Prism 5.0 software (GraphPad280.10  97.17 versus 267.80  61.15 (control box: 227.5-289.75, median: 2
groups showed appropriate hyperlipidemia status (control, n ¼ 10 vs statin, n ¼
treatment) between statin and control groups: 201.50 80.86 versus 190.40 5
251.25, median: 190, 82344). E, Statin group showed effectively decreased T
Tchol level (after statin treatment) between statin and control groups: 181.50 
254, 221311/statin box: 160.75-212.5, median: 175, 65277). F, Statin group
Postimplantation (12 weeks) LDL level (after statin treatment) between statin a
box: 181.25-266, median: 248, 142307/statin- box: 103-159.75, median: 129
The Journal of Thoracic and CaSoftware, Inc, San Diego, Calif). Normal data distribution was determined
using the Shapiro–Wilk test. The Student t test was used to compare mean
blood lipids, Il-6, and BMP-2 expression levels, tissue calcium level, and
the relative density ofWestern blotting level between groups (statin vs con-
trol). For comparison of 4 different valve types, analysis of variance test
was used. The Kruskal–Wallis test and Mann–Whitney test were applied
to test overall/pairwise group mean differences in calcium levels.
RESULTS
Effect of Rosuvastatin on Blood Lipid Profiles and
Body Weight
Rosuvastatin significantly reduced the blood Tchol levels
in hypercholesterolemic animals. The Tchol levels of the 2
groups before administration of the high-fat diet were not
significantly different (Table 1, Figure 2, A). At 4 weeks,
the Tchol levels were significantly increased compared
with the initial levels, and therewas no significant difference
between the groups (Table 1, Figure 2, C). However, at
12 weeks the Tchol level of the statin group was signifi-
cantly lower than that of the control group (P < .001,
Table 1, Figure 2, E). The effect of rosuvastatin on blood
LDL cholesterol level was similar. The LDL cholesterol
levels at the beginning of the experiment and at 4 weeks
were not significantly different between the groups
(Table 1, Figure 2,B andD), but at 12 weeks the statin group
had significantly lower LDL cholesterol than the control
group (P< .001, Table 1, Figure 2, F). Rosuvastatin did
not affect the animals’ body weight change. All of the ani-
mals gained weight every week, and there were no signifi-
cant differences between the groups.
Effect of Rosuvastatin on Calcium Levels in the
Implants
The calcium levels in the tissue valve samples were
measured 12 weeks after implantation. The calcium level
of the control group was significantly higher than that of
the statin group (P < .01) regardless of BHV type
(Table 2, Figure 3,A-D). Therewas no significant difference
in the calcium levels of the different BHV types (P ¼ .62,
Figure E1).
Effect of Rosuvastatin on Cellular Infiltration of the
Bovine Pericardial Implants
Rosuvastatin significantly reduced cellular infiltration of
the pericardial implants in the hypercholesterolemic ani-
mals. Numerous cellular infiltrates were observed around52.5, 208412/statin box: 236.5-347, median: 271.5, 135432). D, Both
10). Postimplantation (4 weeks) LDL level (just before initiation of statin
7.41 (control box: 160.75-190.25, median: 184.5, 129342/statin box: 159-
chol level (control, n ¼ 10 vs statin, n ¼ 10). Postimplantation (12 weeks)
57.12 versus 257.30  30.10, P<.01 (control box: 234.25-268.5, median:
showed effectively decreased LDL level (control, n¼ 10 vs statin, n¼ 10).
nd control group: 130.10  49.35 versus 227.50  57.00, P<.01 (control
, 38215). LDL, Low-density lipoprotein; Tchol, total cholesterol.
rdiovascular Surgery c Volume 158, Number 3 735
TABLE 2. Tissue calcium level in the different prostheses
Calcium level
Statin group Control group P value
Edwards (mg/g) (Irvine,
Calif)
1.31  0.40 2.67  0.26 <.01
Trifecta (mg/g) (St Jude
Medical, St Paul, Minn)
1.63  0.72 2.54  0.42 <.01
Mitroflow (mg/g) (LivaNova,
London, England)
1.26  0.38 2.39  0.71 <.01
Hancock (mg/g) (Medtronic
Inc, Minneapolis, Minn)
1.53  0.34 2.70  0.57 <.01
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Tthe implants, and some of them were also present within the
fibers of the implants. More cellular infiltration was
observed in the control group than in the statin group (con-
trol vs statin: 121.30  23.59 vs 85.30  11.22, P<.01,
Figure 4).Effect of Rosuvastatin on the Expression of the
Proteins Involved in Calcification Metabolism and on
Cell Populations
The immune-staining results showed that the positive cell
count ratios (positive cell/total cell, %) for calcification*
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FIGURE 3. The calcium levels in the extracted BHV samples were measured
significantly higher than that of the statin group (control, n ¼ 160 vs statin, n ¼
aortic valve: 1.31 0.40 versus 2.67 0.26,P<.01 (statin, n¼ 40 vs control, n¼
median: 1.33, 0.721.87). B, Hancock aortic valve: 1.53  0.34 versus 2.70 
median: 2.76, 1.663.35/statin box: 1.69-2.23, median: 1.94, 1.312.51). C,
n ¼ 40 vs control, n ¼ 40) (control box: 1.72-2.86, median: 2.72, 1.233.2/s
1.63 0.72 versus 2.54 0.42, P<.01 (statin, n¼ 40 vs control, n ¼ 40) (cont
1.46, 0.982.92).
736 The Journal of Thoracic and Cardiovascular Surginduction BMP-2 and the inflammatory marker IL-6 were
significantly higher in the control group (control vs statin:
22.94%  4.54% vs 9.97%  1.15%, P < .01;
21.82%  8.19% vs 5.06%  5.96%, P ¼ .02; and
34.63%  6.25% vs 10.37%  3.23%, P<.01, respec-
tively) (Figure 5) (MAC 387: the monoclonal antibody,
which show a similar reaction pattern as antisera to a com-
plex formed by the calcium-binding proteins. Macrophages
were identified by staining tissue sections with commer-
cially available antibodies). The relative band density of
each group is shown in Figure 6, A. Western blotting re-
vealed that BMP-2 and IL-6 expressions were significantly
increased in the control group. However, rosuvastatin
significantly suppressed BMP-2 (109.66%  8.98% vs
16.52%  3.47%, P < .01) and IL-6 (113.08% 
17.78% vs 42.34% 12.98%, P<.01) (Figure 6, B andC).DISCUSSION
Our previous pilot study investigated the effect of rosu-
vastatin on the calcification of bovine pericardial aortic tis-
sue valves in a rat subdermal implantation model.10 The
principal finding of that study was that high cholesterol
levels may be a significant risk factor for bovine pericardial
valve calcification. Statin treatment was able to*
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160, P<.01) regardless of BHV type. A, Carpentier-Edwards Perimount
40) (control box: 2.54-2.81,median: 2.64, 2.213.1/statin box: 1.00-1.60,
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rol box: 2.23-2.89, median: 2.63, 1.913.07/statin box: 1.04-1.92, median:
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FIGURE 4. Rosuvastatin significantly reduced cellular infiltration of the BHV in the hypercholesterolemic rats. Numerous inflammatory cell infiltrates
were observed around the implants, and some of them were also present within the fibers of the implants in control group (upper left); however, the statin
group showed near normal cellular concentration and distribution (upper right) More inflammatory cellular infiltration was observed in the control than in
the statin group (control, n ¼ 160 vs statin, n ¼ 160: 121.30  23.59 vs 85.30  11.22, P<.01) (lower figure). H&E, Hematoxylin–eosin.
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valves in a subcutaneous rat model and had the dual effect
of anticalcification and anti-inflammation regardless of hy-
percholesterolemia. However, our previous experiment was
performed using just one type of bioprosthesis (Carpentier-
Edwards Perimount aortic valve). Therefore, we wanted to
evaluate the effect of statin treatment on other popular types
of bioprostheses, including onemadewith a different source
material (the Medtronic Hancock II valve made of porcine
pericardial tissue), and to re-verify statin’s anticalcification
and anti-inflammation effects on bovine pericardial bio-
prostheses. To simplify the study groups, we used only
the hypercholesterolemia rat model for proving the statin
effect on bioprosthesis in a recent experiment. In our previ-
ous experiment, to clearly show the effect of statin treat-
ment, we classified animals into 4 groups according to
hypercholesterolemia and statin intake to observe the
effect of statin treatment on both nonhyperlipidemia and
hyperlipidemia. Our results showed a strong effect of statin
treatment for preventing hypercholesterolemia and anti-
inflammatory reactions from inhibition of cellular infiltrates
and IL-6 activation (Figure 7). Also, normal calciumThe Journal of Thoracic and Cadeposition was found in both statin treatment groups regard-
less of cholesterol level.
Farivar and Cohn5 reported that increasing serum choles-
terol levels are associated with increased BHV calcification.
They found that patients who had their valves explanted had
higher serum cholesterol levels than an age, survival dura-
tion, and valve-position–matched group with nonexplanted
valves (189 vs 163 mg/dL, P<.001), and the odds ratio for
valve explantation was 3.9-fold higher in patients whose
serum cholesterol levels were greater than 200 mg/dL. Palta
and colleagues8 also reported that patients with a serum
cholesterol level greater than 200 mg/dL had a native aortic
valve area reduction rate approximately twice that of those
with a lower cholesterol level (P¼ .04). However, based on
a review of published studies, Gilmanov and colleagues12
found that although the data are conflicting, statin therapy
does not prevent structural valve deterioration of BHV in
the aortic position. Likewise, Bellamy and colleagues13
found no correlation between the rate of progression of
aortic stenosis and cholesterol levels in 157 patients,
although statin treatment was associated with slower pro-
gression: Aortic valve area decreased by 3 mm  10%rdiovascular Surgery c Volume 158, Number 3 737
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FIGURE 5. The immune-staining results in BHV showed that the positive cell count ratios (positive cell/total cell,%) for calcification induction (MAC
387, BMP-2) and the inflammatory marker IL-6 were significantly higher in the control group (control, n¼ 160 vs statin, n¼ 160). This result showed statin
can reduce both calcification and inflammation. A and B, MAC 387, 22.94% 4.54% (control) versus 9.97% 1.15% (statin), P<.01 (control box: 20.5-
23.82, median: 21.42, 19.329.5/statin box: 9.58-10.71, median: 10.33, 8.310.8). C and D, Il-6, 34.63%  6.25% (control) versus 10.37%  3.23%
(statin), P<.01 (control box: 32.2-38.3, median: 36.03, 26.040.4/statin box: 8.08-12.7, median: 10.5, 6.813.6). E and F, BMP-2, 21.82%  8.19%
(control) versus 5.06%  5.96% (statin), P ¼ .02 (control box: 17.8-23.8, median: 19.95, 1433.3/statin box: 0-9.4, median: 4.34, 011.5).MAC, Anti-
macrophage; IL, interleukin; BMP-2, bone morphogenetic protein 2.
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7 mm  13% per year in untreated patients. Kulik and col-
leagues14 analyzed 1193 patients who underwent aortic
valve replacement with a contemporary bioprosthesis, 150
of whom received lipid-lowering therapy (LLT) early after
surgery and were compared with patients who did not
receive LTT. They found no association between early post-
operative LLT and a slowing of bioprosthesis structural
valve degeneration, and concluded that with the excellent
durability of BHV in the current era, a prospective738 The Journal of Thoracic and Cardiovascular Surgrandomized trial of statin therapy to prevent bioprosthetic
structural valve degeneration does not appear to be justified,
let alone feasible.14 Unfortunately, until now, no clinical tri-
als have been run long enough to determine if statins have a
significant benefit in preventing structural valve deteriora-
tion, and all of the retrospective studies are confounded
by hypercholesterol (or coronary artery disease) indications
for statin initiation. A recent animal experimental study15
using bovine pericardial bioprostheses in a rat subdermal
implantation model showed that atorvastatin treatmentery c September 2019
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FIGURE 6. Western blotting in BHV results for inflammatory markers. A,
The relative band density of each group. Western blotting revealed that
BMP-2 and IL-6 expressions were significantly increased in the control
group. However, rosuvastatin significantly suppressed BMP-2 (control,
n ¼ 160 vs statin, n ¼ 160). A, Band density of each group for
inflammatory markers and BMP-2. B, IL-6, 113.08%  17.78% (control)
versus 42.34%  12.98% (statin), P<.01. C, BMP-2 109.66%  8.98%
(control) versus 16.52%  3.47% (statin), P < .01. IL, Interleukin;
BMP-2, bone morphogenetic protein 2.
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global extent of inflammatory infiltrates. Lorusso and col-
leagues15 suggested that atorvastatin significantly attenu-
ates the postimplantation structural degeneration of
bovine valve tissue in a subcutaneous animal model.The Journal of Thoracic and CaHowever, the correlation between lipid deposition and bio-
prosthesis calcification was not clear, because the hypercho-
lesterolemia condition was not investigated. Because
hypercholesterolemia is the optimal condition in which to
observe a correlation between lipids and BHV, we adopted
the concept of the previous experiment and made a high
lipid-profile rat model. In our previous study, we suggested
that hypercholesterolemia is clearly associated with BHV
calcification. Moreover, our results indicated that statin
treatment can prevent postimplant calcification and inflam-
matory infiltration in an animal model.10 It has been re-
ported that cholesterol deposition may play an important
role in long-term structural valve degeneration even in indi-
viduals with normal lipid profiles. The deposition of LDL-C
particles on the external surface of the valve leaflets initiates
a chronic inflammatory reaction, which, over a long period
of time, leads to calcification, scarring, and leaflet
dysfunction.16
In real-world situations, there are various types of BHV
for heart valve surgery, and we could not conclude from
our previous experiment that statin treatment has the same
effect on bovine and porcine pericardial tissue valves.
Therefore, we included different types of BHV in this
experiment and re-verified the effect on bovine pericardial
valve tissue (including the Carpentier-Edwards Perimount
aortic valve). Our results revealed that all of the BHVs
showed a similar calcification tendency regardless of statin
intake (Figure 3). The correlation of increased cholesterol
levels with BHV calcification leads to speculation about
the mechanism involved.17 Additionally, oxidized LDL
cholesterol, which interacts with T lymphocytes and cal-
cium, has been demonstrated in degenerative aortic valve
stenosis.18 The hypothesis of pathophysiologic similarity
among atherosclerosis, bioprosthetic degeneration, and
native valve degeneration has recently been suggested, indi-
cating new directions of research, particularly into treat-
ment and prevention options.8,9,19 However, the role of
hypercholesterolemia in BHV degeneration remains
unclear. Lorusso and colleagues14 reported a clear reduction
of calcium deposition in the pericardial tissue explanted
from animals on statin therapy, in terms of both microcalci-
fication and global calcium content. Our previous results re-
vealed strong effects of statin treatment in preventing
hypercholesterolemia and promoting an anti-inflammatory
reaction, as proven by inhibition of cellular infiltrates and
IL-6 activation. In addition, a marked reduction of calcium
deposition and BMP-2 expression related to calcium meta-
bolism was found in the statin-treated groups. We found
the same strong effects on hypercholesterolemia, anti-
inflammatory reactions, and BMP-2 expression in the
current study.
It is well known that BMP is the most important factor in
calcification signaling pathways, and it has been shown that
BMP signaling is required for the development of aorticrdiovascular Surgery c Volume 158, Number 3 739
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FIGURE 7. Statin attenuated bioprosthetic valve calcification. BMP-2, Bone morphogenetic protein 2; IL, interleukin.
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strongly inhibit inflammatory mediators such as IL-6, and
this anti-inflammatory mechanism might consequentially
downregulate BMP-2 in valve tissue. Osman and col-
leagues21 suggested that interstitial cells in human valves
are capable of osteoblastic differentiation by potential me-
diators that could be pharmacologically targeted by statins
to cause the downregulation of BMP-2. This suggestion is
in accord with our findings of BMP-2 downregulation.
Finally, aortic valve stenosis is also characterized by accu-
mulation of oxidized LDL and T-lymphocytes, thus filling
tissue inflammation and the release of proinflammatory cy-
tokines such as tumor necrosis factor-a and IL-1a, which in
turn induce cell proliferation. Calcification and osteogene-
sis, mediated by inflammation and processes involving740 The Journal of Thoracic and Cardiovascular Surgmetalloproteinases, have been identified as players in the
pathogenesis of aortic stenosis, so statin as a strong anti-
inflammation agent might play an important role for slow-
ing or preventing calcification.22
Study Limitations
The limitations of this study are the relatively small num-
ber of animals used in the experiments and the fact that tis-
sue implantation in a subcutaneous animal model has some
differences from the blood circulation model. Therefore,
our data should be interpreted with caution. Juvenile sheep
are widely used because tests can be done in the systemic
circulation. However, these are complex, time-consuming,
and expensive. Easier and less-expensive study setups as a
first step in developing tissue-engineered heart valves areery c September 2019
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contact of host tissue with implanted specimens leading to
rapid cellular infiltration. Because of the subdermal posi-
tion, an absence of bloodstream and mechanical stress oc-
curs, which influences cellular repopulation. Because of
these limitations, the rat subdermal model can only provide
basic information about immunologic reactions and recellu-
larization.23 In addition, the resected prosthetic valve cusps
were already injured at the time of cutting, so the continuity
of the coated membrane was broken before implantation.
Compared with unresected valve cusps, this experimental
situation might favor cellular infiltration from the host sys-
tem, which can induce inflammation and calcification.
Third, in this experiment, we did not set and measure the
calcification degree in the normal cholesterol group with
or without statin for each bioprosthetic, so we cannot decide
which is the more dominant factor for reducing calcification
between the anti-lipid and anti-inflammatory effects.
Finally, the relationship between tissue valve calcification
mitigation in animal model studies and clinical outcomes
has not been established.CONCLUSIONS
High cholesterol levels may be a significant risk factor for
the calcification of any type of bioprosthetic aortic valve.
Statin treatment significantly attenuated the calcification
of bovine and porcine bioprosthetic aortic valves in a
subcutaneous rat model and had dual anticalcification and
anti-inflammation effects. Our results suggest that statin
treatment might be helpful for the longevity of BHVs.Conflict of Interest Statement
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